Below you can read the official version of events from Business of Cannabis .
A word to the wise here.
Curaleaf have a plan that involves direct access to the NHS and now “sponsorship” / “involvement” in CPD for medical professionals wishing to involve themselves in cannabis.
I’d suggest that one company that’s already used very aggressive tactics in the US to ensure market share having this level of influence in the provision of medical cannabis and management thereof in the UK through these types of arrangements is in no way healthy for medical cannabis development in the country and will contribute to policy arguments to limit adult use in the future as well.
Here’s the report
Business of Cannabis
Healthcare professionals attending the Cannabis Health Symposium in London next month will be able to gain Continuing Professional Development (CPD) points, supporting their ongoing professional training and education.
The inaugural event, which takes place on Tuesday, November 25, at Conway Hall, has received CPD accreditation in principle from the CPD Certification Service. This recognition confirms that the symposium meets rigorous standards for educational quality, structure, and relevance, ensuring attendees benefit from a credible, evidence-based learning experience.
Professional development for clinicians in medical cannabis
The symposium is designed to offer UK healthcare professionals clinically grounded and expert-led education on cannabis-based products for medicinal use (CBPMs).
It will feature presentations, case studies, and workshops focused on enhancing clinical understanding and improving patient care.
CPD, which refers to the ongoing education of healthcare practitioners after formal qualification, is essential to ensure clinicians maintain up-to-date knowledge and safe practice.
In emerging fields such as medical cannabis, accredited learning opportunities also help build confidence and expertise among prescribers.
Currently, only around 180 doctors on the GMC Specialist Register are actively prescribing medical cannabis, representing less than 1% of those authorised to do so.
With around 80,000 patients expected to receive CBPM treatment in the UK by 2025, there is a pressing need for more trained prescribers to meet patient demand and uphold care standards.
What to expect from the event
The symposium will explore topics such as clinical governance, NHS integration, product consistency and safety, and the science of the endocannabinoid system. Expert speakers will present the latest evidence on the use of cannabis-based medicines in women’s health, psychiatry, neurodivergence, and neurodegenerative conditions.
Alongside the main programme, a workshop series led by the Medical Cannabis Clinicians Society (MCCS) will provide hands-on, skills-based training. These sessions will introduce the fundamentals of medical cannabis prescribing, including formulations, clinical indications, safety considerations, and professional responsibilities. Participants will have opportunities to engage directly with experienced prescribers through Q&A sessions and interactive learning.
Professor Mike Barnes, Chair of the MCCS, said the symposium would represent a ‘significant step forward for clinicians’, with the potential to benefit ‘many thousands of patients’ across the UK.
Accredited training and certification
Organised in partnership with Curaleaf Laboratories and the Medical Cannabis Clinicians Society, the symposium aims to empower healthcare professionals to integrate cannabis-based treatments into their clinical practice confidently.
Clinicians will receive CPD points for each session attended, with formal certification provided after the event.
